Managing the Risk of Nitrosamine Impurities

The Commissioner’s National Priority Voucher can be used by drug developers to participate in a novel priority program for shortened drug approval review time.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

NMPA’s Center for Drug Evaluation accepted Merck KGaA’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with TGCTs that require systemic treatment.

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

The new lab will be used to develop and scale innovations for the production of medicines and to help secure the supply chain.

EMA has published recommendations to address potential radiopharmaceutical shortages.